Dr Reddy’s Labs Q4 Results: PAT sees nine-fold jump to Rs 960 crore, dividend declared at Rs 40/share

Indian pharmaceutical major Dr Reddy’s Laboratories reports a whopping 890% YoY growth in net profit. Revenue from operations stood at Rs 5,843 crore, up 15.28% YoY, while total expenses fell by 4% to Rs 5,132.2 crore. Company recommends a final dividend of Rs 40 per share for the financial year 2022-23